UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038353
Receipt number R000043707
Scientific Title Evaluation of titin N-fragment in urine as a marker of muscle catabolism in intensive care
Date of disclosure of the study information 2019/10/21
Last modified on 2019/10/21 17:08:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of titin N-fragment in urine as a marker of muscle catabolism in intensive care

Acronym

Evaluation of titin N-fragment in urine as a marker of muscle catabolism in intensive care

Scientific Title

Evaluation of titin N-fragment in urine as a marker of muscle catabolism in intensive care

Scientific Title:Acronym

Evaluation of titin N-fragment in urine as a marker of muscle catabolism in intensive care

Region

Japan


Condition

Condition

post intensive care syndrome

Classification by specialty

Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In order to assess muscle atrophy in intensive care, imaging tests is performed at present.
We evaluate whether urinary titin fragments, a more objective and minimally invasive muscle catabolism marker, correlate with muscle atrophy associated with intensive care.

Basic objectives2

Others

Basic objectives -Others

To examine whether changes in urinary titin fragment values in patients undergoing intensive care correlate with changes in thigh muscle mass assessed by CT on days 1 and 10.

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

correlation between titin fragment in urine and femoral muscle mass change in 10 days evaluated by CT

Key secondary outcomes

correlation between titin fragment in urine and SOFA score, inflammation marker, calorie intake or protein intake


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

ICU admission patients over 20 years old
Patients expected to be hospitalized for 10 days or longer
Patients who have obtained consent from the person or a representative

Key exclusion criteria

Pregnant women
Under 35 years old or women who can get pregnant
Patients without self urine
Patients who have difficulty measuring thigh muscle mass after trauma or amputation
ECMO patients
Other patients who are determined to be inappropriate as subjects by the principal investigator

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Hidehiko
Middle name
Last name nakano

Organization

Hitachi General Hospital

Division name

Department of Emergency and Critical Care Medicine

Zip code

317-0077

Address

2-1-1, Jonancho, Hitachi, Ibaraki, Japan

TEL

0294-23-1111

Email

be.rann1988jp@gmail.com


Public contact

Name of contact person

1st name Hidehiko
Middle name
Last name Nakano

Organization

Hitachi General Hospital

Division name

Department of Emergency and Critical Care Medicine, Hitachi General Hospital

Zip code

317-0077

Address

2-1-1, Jonancho, Hitachi, Ibaraki, Japan

TEL

0294-23-1111

Homepage URL


Email

be.rann1988jp@gmail.com


Sponsor or person

Institute

Department of Emergency and Critical Care Medicine, Hitachi General Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hitachi General Hospital Institutional Review Board

Address

2-1-1, Jonancho, Hitachi, Ibaraki, Japan

Tel

0294-23-1111

Email

hitachi.chiken.ha@hitachi.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 10 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 10 Month 21 Day

Date of IRB

2019 Year 10 Month 18 Day

Anticipated trial start date

2019 Year 10 Month 21 Day

Last follow-up date

2020 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

none


Management information

Registered date

2019 Year 10 Month 21 Day

Last modified on

2019 Year 10 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043707


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name